"Cardiotoxicity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Descriptor ID |
D066126
|
| MeSH Number(s) |
C23.550.161 C25.100.389 C26.733.266 G01.750.748.500.266
|
| Concept/Terms |
Cardiotoxicity- Cardiotoxicity
- Cardiotoxicities
- Cardiac Toxicity
- Cardiac Toxicities
- Toxicities, Cardiac
- Toxicity, Cardiac
|
Below are MeSH descriptors whose meaning is more general than "Cardiotoxicity".
Below are MeSH descriptors whose meaning is more specific than "Cardiotoxicity".
This graph shows the total number of publications written about "Cardiotoxicity" by people in this website by year, and whether "Cardiotoxicity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 3 | 5 | 8 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 3 | 4 |
| 2026 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotoxicity" by people in Profiles.
-
Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All. Curr Heart Fail Rep. 2026 Jul 22; 23(1).
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation. 2026 Aug 04; 154(5):e188-e205.
-
Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study. ESC Heart Fail. 2026 May 05; 13(3).
-
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers. Cancer Med. 2026 Apr; 15(4):e71682.
-
Radiation Doses to Cardiac Substructures Predict Elevation in High-sensitivity Cardiac Troponin T Levels in Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar 15; 124(4):1124-1136.
-
Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025 Nov; 27(11):2152-2167.
-
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. Circulation. 2025 Apr 15; 151(15):e926-e943.
-
Doxorubicin-induced phosphorylation of lamin A/C enhances DNMT1 and activates cardiomyocyte death via suppressing GATA-4 and Bcl-xL in rat heart. Biochim Biophys Acta Mol Basis Dis. 2025 03; 1871(3):167692.
-
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. J Card Fail. 2025 02; 31(2):415-455.